Stanley Capital Partners has invested in a majority stake in French pharmaceutical group Laboratoire XO. Founded in 2015, Lab XO specialises in mature market authorisations to sell and market drugs across various therapeutic areas such as pain, central nervous system, cardiology, oral care, and women’s health.
The company attained a turnover of €60m, owns 26 brands and a distribution network of more than 45 countries.
SCP said it will be actively working with Lab XO’s management team to strengthen and develop the company through its next phase of growth, and looking to use it as a platform investment with further add-on investments in the pipeline.
Lab XO had carried out 18 add-on acquisitions to-date.
The completion of this investment brings SCP to assets under management to $440 million.
